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ABSTRACT 
Objective: This study aimed to investigate whether quercetin is able to improve the efficacy of sorafenib in triple negative breast cancer cells and 
explore the possibility of drug efflux transporters modulation by quercetin.  
Methods: We exposed MDA-MB-231, a triple negative breast cancer cell line, to several groups: sorafenib alone, quercetin alone, a combination of 
sorafenib-quercetin, and control. We determined cell viability over control weekly up to 4 w. At the end of the fourth week, mRNA expressions of drug 
efflux transporters (P-glycoprotein and breast cancer resistance protein [BCRP] and MRP2 [multidrug resistance-associated protein-2]) were examined.  
Results: Sorafenib alone was shown to maintain its efficacy for only two weeks, while quercetin alone was able to maintain its effect for four weeks. 
A combination of sorafenib-quercetin showed the best cytotoxicity effects compared with sorafenib or quercetin alone and was able to maintain its 
efficacy for four weeks. There were increased mRNA expressions of P-glycoprotein, BCRP, and MRP2 after four weeks of treatment with sorafenib, 
while treatment with quercetin decreased the drug efflux transporters expressions. A combination of sorafenib-quercetin decreased the mRNA 
expressions of both P-glycoprotein and BCRP, compared with sorafenib alone.  
Keywords: BCRP, MRP2, P-glycoprotein, Quercetin, Sorafenib  
Conclusion: We suggest that decreased expressions of both drug efflux transporters, P-glycoprotein and BCRP, mediated by quercetin ameliorate 
the efficacy of sorafenib in TNBC. Therefore, the addition of quercetin to sorafenib might be useful in the future in improving the therapeutic efficacy 
of sorafenib in triple negative breast cancer. 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ijap.2019.v11s6.33576 
 
INTRODUCTION 
Breast cancer remains the most common type of malignancy for 
women around the world, including in the Asia-Pacific region, which 
accounts for 18% of all cancer diagnosed [1]. Despite the advances 
in early diagnosis and adjuvant treatment of this disease, many 
women still relapse with metastatic breast cancer [2]. 
Breast cancer is a heterogenous disease with diverse morphologies, 
molecular profiles, and responses to treatment [3]. About 10–20% of 
all breast cancers found are triple negative breast cancer (TNBC). 
TNBC is one particular type of cancer characterized by the lack of 
estrogen and progesterone receptors, as well as the absence of HER-2 
protein expressions [3-5]. To date, TNBC is still an important clinical 
challenge, because these cancers do not respond to endocrine therapy 
or other available targeted agents [4]. Chemotherapy is still the 
treatment of choice for TNBC, though most patients do not achieve 
complete remission after chemotherapy. These problems have 
generated many studies into identifying an effective therapeutic 
strategy for TNBCs [5]. Current available treatment options for TNBC 
include anthracyclines, taxanes, platinum compounds, and some 
newer targeted therapy, including tyrosine kinase inhibitors [6]. 
One of the oral tyrosine kinase inhibitors used in breast cancer treatment 
is sorafenib. Sorafenib inhibits tumor growth and proliferation by 
interfering with several receptor tyrosine kinases involved in the 
pathogenesis of malignant breast cancer
Quercetin is a natural polyphenol that has been shown to exert 
anticancer activities in triple negative breast cancer cells through 
targeting the Akt/mammalian target of the rapamycin (mTOR) pathway 
in combination with the tyrosine kinase inhibitor, gefitinib [9]. Quercetin 
was also shown to regulate β-catenin signaling and downregulate 
vimentin in TNBC, thus it may potentiate existing chemotherapeutic 
drugs [10].  
 cells [7]. Unfortunately, an 
accumulating evidence showed that there was a tendency of increased 
acquired resistance to tyrosine kinase therapy. The known molecular 
mechanism of cancer cell resistance to tyrosine kinase inhibitors 
includes the mutation in kinase domains, epithelial mesenchymal 
transition, hypoxic microenvironment, and overexpression of ABC 
transporters [8].  
In the present study, we aimed to investigate whether quercetin 
might improve the therapeutic efficacy of sorafenib in triple negative 
breast cancers and to explore the possibility of drug efflux 
transporters modulation by quercetin.  
MATERIALS AND METHODS  
Materials 
The MDA-MB-231 triple negative breast cancer cell line was a kind 
gift from the Tsukuba University Laboratory in Japan. Sorafenib was 
obtained from Santa Cruz; quercetin and DMSO were purchased 
from Sigma-Aldrich (Singapore). Dubelco Minimal Essential Medium 
(DMEM), Fetal Bovine Serum (FBS), penicillin/streptomycin, 
Fungizone, and Dubelco Phosphate Buffer Solution (D-PBS) were 
obtained from Biowest, USA. RNA isolation reagents, the 
Transcriptor First Strand cDNA Synthesis kit, and the FastStart DNA 
master SYBR Green I kit were purchased from Roche Diagnostics 
(Singapore); primers were obtained from 1st
Cell cultures 
 BASE Ltd, Singapore.  
The MDA-MB-231 cells were cultured and maintained in DMEM 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 
mmol L-glutamine, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 
1% Fungizone. The cells were subcultured when they reached about 
90% confluency. 
MTS assay 
The MTS assay was used to determine the cytotoxicity concentration 
50% of sorafenib and quercetin on MDA-MB-231. The CC50 found 
from this assay will be further used in drug treatment using 
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sorafenib and quercetin. We applied sorafenib or quercetin three 
times in one week to obtain the repeated dose CC50. 
Drug treatment 
The MDA-MB-231 were plated at 10,000 cells per well and were 
treated with a medium containing sorafenib, quercetin, sorafenib 
and quercetin, or control (DMSO) in a 6-well plate. The sorafenib 
and quercetin were dissolved in DMSO at a final concentration of 
less than 0.001%. Every week, the cells were trypsinized, counted, 
and 10,000 cells were re-plated in a new 6-well plate. Sorafenib with 
or without quercetin were given at the time of medium change, 
which was three times per week.  
Cell viability assay  
The cell viability assay was performed using the trypan blue exclusion 
method. The number of viable cells were counted using the trypan 
blue dye exclusion in a hemocytometer. The results were presented as 
the percentage of viable cells relative to the control group (DMSO).  
Quantitative reverse transcriptase PCR analysis  
The total cellular RNA was extracted from 1,000,000 cells after 
trypsinization using the Total RNA Mini Kit (Geneaid, Taiwan) 
according to the manufacturer’s protocol. Afterwards, 1 µg of RNA 
was converted to cDNA using the Transcriptor First Strand cDNA 
Synthesis kit (Roche Diagnostics, Singapore).  
The quantity and purity of the RNA and cDNA obtained were 
determined using NanoDrop Spectrophotometer (Thermo Scientific, 
USA). The cDNA obtained was then subjected to quantitative real-
time reverse transcription polymerase chain reactions (qRT-PCR). 
qRT-PCR 
The mRNA expressions of the following drug transporters were 
quantified: P-glycoprotein, MRP2 (multidrug resistance protein-2), 
and BCRP (breast cancer resistance protein). A quantitative real-time 
reverse transcription polymerase chain reaction (qRT-PCR) was 
performed using the FastStart DNA master SYBR Green I kit (Roche, 
USA) on the Light Cycler Nano (Roche, USA) PCR Detection System. 
The following primers used were: P-glycoprotein, Fwd: 
TTACATTCAGGTTTCATTTTGGTG; Rev: TCCTGTCGCATTATAGCATGA; 
BCRP, Fwd: TTCGGCTTGCAACAACTATG; Rev: TCCAGACACAC -
CACGGATAA; MRP2, Fwd: ACAGAGGCTGGTGGCAACC; Rev: ACCAT -
TACCTTGTCACTGTCCATGA; β-actin (housekeeping gene): Fwd: 
GCTGGAAGGTGGACAGCGA, Rev GGCATCGTGATGGACTCCG.  
A total of 20 µl reactions were performed in a 32-well plate on 
the qRT-PCR LightCycler Nano (Roche, USA). The RT-PCR 
conditions were set at a 3-step amplification (45 cycles) in a 
specific annealing temperature of 52 ° for P-glycoprotein and 
BCRP, and 53 ° for MRP2.  
The quantification cycle (Cq) was analyzed by relative quantification 
using the Livak method and described as normalized expression 
ratios of P-glycoprotein, BCRP, and MRP2 to β-actin. 
Data analysis  
The data were presented in the form of means ± standard deviation 
(SD). Graphs were created using GraphPad Prism software 7 
(GraphPad, USA). The statistical significance was calculated using 
ANOVA One-Way, followed by a post hoc tests, with p<0.05 considered 
as significant. 
RESULTS  
We obtained cytotoxicity concentrations of 0.6 µM and 46.9 µM, 
respectively, for sorafenib and quercetin after repeated treatment in 
MDA-MB-231 (table 1). Based on the CC50 obtained after repeated-
dose administration, we used sorafenib at concentrations of 0.6 µM 
and 0.3 µM, while for quercetin we used 25 µM and 12.5 µM for 
further experiments in MDA-MB-231. 
 
Table 1: Cytotoxicity concentration 50% (CC50) of sorafenib and quercetin after repeated dose 
 CC50 
Sorafenib   0.6 µM  
Quercetin  46.9 µM 
Direct observation of MDA-MB-231 after four weeks of treatment did not cause visible changes in morphology, as seen throughout all treatment 




B. Sorafenib 0.3 
 
C. Sorafenib 0.6 
 
D. Quercetin 25 
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A. Sora 0.3+Q 12.5 
 
E. Sora 0.6+Q25 
 
Fig. 1: Morphology of MDA-MB-231 cells after four weeks of treatment of A) control, B) quercetin 25 µM, C) sorafenib 0.3 µM, D) sorafenib 
0.6 µm, E) sorafenib 0.3 µM+quercetin 12.5 µM, sorafenib 0.6 µM+quercetin 25 µM. Cells were observed using an inverted microscope at 
20 x magnification 
 
  
After continuous treatment with for 4 w, it was shown that sorafenib 
alone was shown to maintain its efficacy for only two weeks, while 
quercetin alone was able to maintain its effect for four weeks. Fig. 2 
showed that quercetin alone has a better cytotoxicity effect compared 
to the sorafenib-combination at weeks three and four. There was a 
marked increase of P-glycoprotein mRNA expressions in the sorafenib 
group and the effect was shown to be dose-dependent. Quercetin alone 
tended to decrease the expression of P-glycoprotein. A combination of 
sorafenib and quercetin at a higher dose significantly decreased P-
glycoprotein expressions, but not in the lower dose (fig. 3). 
 
Fig. 2: Percentage of cell viability over control after four weeks of treatment with control (DMSO) or sorafenib 0.6 µM, sorafenib 0.3 µM, 
quercetin 25 µM, sorafenib 0.6 µM+quercetin 25 µM, or sorafenib 0.3 µM+quercetin 12.5 µM 
 
 
Fig. 3: mRNA expression of P-glycoprotein (normalized to β-actin) after four weeks of treatment with control (DMSO) or sorafenib 0.6 µM, 
sorafenib 0.3 µM, quercetin 25 µM, sorafenib 0.6 µM+quercetin 25 µM, or sorafenib 0.3 µM+quercetin 12.5 µM, Data are expressed as 
means ± SD of four experiments. *significantly different at p<0.05, **significantly different at p<0.001 
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Increased BCRP mRNA expressions were shown in the sorafenib 
group and appeared to be dose-dependent. Quercetin alone 
resulted in a significant decrease of BCRP mRNA expressions. A 
combination of sorafenib and quercetin lowered BCRP 
expressions in sorafenib+quercetin groups versus sorafenib 
alone (fig. 4). 
 
 
Fig. 4: mRNA expression of BCRP (normalized to β-actin) after four weeks of treatment with control (DMSO) or sorafenib 0.6 µm, 
sorafenib 0.3 µM, quercetin 25 µM, sorafenib 0.6 µM+quercetin 25 µM, or sorafenib 0.3 µM+quercetin 12.5 µm, Data are expressed as 
means  SD of fou r  expe r im en ts. *s ign ifican t ly d iffe r en t  a t  p<0 .05 , **sign ifican t ly d iffe r en t  a t  p<0 .001 
  
There was a marked increase in MRP2 mRNA expressions in the high 
dose sorafenib group. Quercetin tended to lower MRP2 expressions 
compared to the control. Lower MRP2 mRNA expressions were achieved 
in both sorafenib+quercetin groups versus sorafenib alone (fig. 5). 
 
 
Fig. 5: mRNA expression of MRP2 (normalized to β-actin) after four weeks of treatment with control (DMSO) or sorafenib 0.6 µM, 
sorafenib 0.3 µM, quercetin 25 µM, sorafenib 0.6 µM+quercetin 25 µM, or sorafenib 0.3 µM+quercetin 12.5 µM, Data are expressed as 
means  SD of fou r  expe r im en ts. *s ign ifican t ly d iffe r en t  a t  p<0 .05 , **sign ifican t ly d iffe r en t  a t  p<0 .001 
DISCUSSION 
Triple negative breast cancer is one of the most aggressive breast 
cancer types and is characterized by poor prognosis and a lack of 
treatment options [11]. Sorafenib is a multi-kinase inhibitor that has 
been used in clinical trial for breast cancer as a single agent or in 
combination with standard chemotherapy in advanced breast cancer 
[12-15]. Previous findings had confirmed that in metastatic breast 
cancer, single-agent sorafenib was not recommended due to the 
short time of the disease progression, [16] however, combinations of 
chemotherapeutic agents seemed promising [13] However, the place 
of sorafenib in the treatment of triple negative breast cancer has not 
yet been determined.  
In our model of triple negative breast cancer cells, we found that 
sorafenib that was applied at CC50 had sufficient cytotoxicity effects 
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only in the first two weeks of treatment; afterwards, the cancer cells 
quickly developed resistance towards sorafenib. Limited data are 
available explaining the mechanism of resistance of breast cancer 
cells to sorafenib. However, studies in hepatocellular carcinoma 
have revealed that several mechanisms may account for an acquired 
resistance to sorafenib, which includes overexpression of multi-drug 
resistance protein, that lead to the increased of drug efflux [17]. The 
combination of sorafenib and quercetin were shown to improve the 
cytotoxicity effect of sorafenib, while quercetin alone was able to 
steadily maintain its effects up to four weeks. To the best of our 
knowledge, this is the first to show a consistent effect of quercetin in 
a long-term application in triple negative breast cancer cells. 
Previous findings in triple negative breast cancer cells MDA-MB-231 
and MDA-MB-468 using quercetin at concentrations ranging from 
10–50 µM in a shorter term of treatment (48 hour and 72 hour) 
proved that quercetin reduced the proliferation and viability of cells 
by regulating β-catenin signaling, inhibiting cell migration, altering 
vimentin and E-cadherin expression levels, and inhibiting the 
Akt/AMPK/mammalian target of rapamycin (mTOR) signaling 
cascade [9, 10]. 
Our results showed that sorafenib in all the doses tested increased 
P-glycoprotein mRNA expressions. This is in accordance with the 
previous study by Harmsen et al. in 2013, which reported that 
tyrosine kinase inhibitors, including sorafenib, were able to induce 
the expression of P-glycoprotein with a short period of 48 h in LS180 
cells. They also showed that the upregulation of P-glycoprotein was 
mediated by pregnane X receptor (PXR) induction [18]. Previous 
studies on quercetin reported that quercetin is a potent inhibitor of 
P-glycoprotein expressions, [19] while in our results, though not 
significant, quercetin alone tended to decrease P-gp expressions. A 
combination of quercetin and sorafenib provided decreased 
expressions in P-glycoprotein compared with sorafenib alone. The 
results by Limtraku et al. (2005) also confirmed that quercetin and 
kaempferol inhibit the P-glycoprotein function in human cervical 
carcinoma KB-V1 cells (with high P-gp expressions) [20].  
The above data suggested that sorafenib increased and quercetin 
strongly decreased BCRP mRNA expressions, while a combination of 
sorafenib and quercetin consistently lowered BCRP expressions. The 
study by Huang et al. in 2013 on short term treatment of sorafenib in 
hepatocellular carcinoma cells found that sorafenib leads to BCRP 
inhibition [21] Reports by Agarwal et al. [22] and Lagas et al.[23] state 
that sorafenib is a substrate of BCRP treatment [22,23]. Polyphenols 
(resveratrol, hesperetin, quervetin, daidzein, and silymarin) were 
shown to interact with BCRP in breast cancer cells of MCF7/MR 
(mitoxantrone resistant) and K562/BCRP cells, and this leads to 
increased accumulation of mitoxantrone in the cells [24].  
Our data showed a marked increase in MRP2 mRNA expressions 
after long-term sorafenib treatment, and these expressions were 
lowered significantly in combination with quercetin. Our result is in 
agreement with Shibayama et al. (2011), who showed that sorafenib 
at CC50 increased MRP2 expressions by 6.4 times in renal cell 
carcinoma. That study also showed that sorafenib is a substrate for 
MRP2, suggesting that MRP2 may implicate drug resistance to 
sorafenib [17] The study by van Zanden et al. suggested that 
quercetin, or flavonoids in general, might worked as inhibitors to 
overcome MRP-mediated multidrug resistance [25]  
Overall, our results indicate that quercetin is able to reduce the 
expressions of P-glycoprotein and also breast cancer resistance 
protein (BCRP) and MRP2 levels in TNBC cells. Further, the cellular 
upregulation of drug efflux transporters is also altered by quercetin 
treatment. Interestingly, quercetin alone was shown to maintain its 
cytotoxic effect in long-term treatment in triple negative breast 
cancer cells, which in our data might be due to the ability of 
quercetin to maintain a low expression of drug efflux transporters. 
Study by Srinivasan et al. [26] has also confirmed that quercetin is 
capable of inhibiting chemotherapy-induced TGF-β signaling in 
TNBC cells, and that it would decrease the development of 
chemotherapy resistance in TNBC. Further, quercetin is able to 
inhibit the enhanced migration and mammosphere formation in 
chemoresistant TNBC cells [26]. Taken together, our findings 
revealed that quercetin is a promising natural product that increases 
the anti-cancer effect of chemotherapy drugs in TNBC. Further 
studies in animal models are needed to confirm the therapeutic 
effect of quercetin in TNBC.  
CONCLUSION 
In conclusion, we suggest that decreased expressions of both drug 
efflux transporters mediated by quercetin ameliorate the efficacy of 
sorafenib in TNBC. Therefore, the addition of quercetin to sorafenib 
might have be useful in the future in improving the therapeutic 
efficacy of sorafenib in triple negative breast cancer.  
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